- ORIGINAL
- Published:
Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study
The Journal of Headache and Pain volume 4, pages 146–151 (2003)
Abstract
The purpose of this study was to determine the safety and efficacy of botulinum toxin type A (BOTOX; Allergan, Irvine, USA) in migraine prophylaxis. We performed a double-blind, randomized, 90-day placebo-controlled study that enrolled 30 adult migraineurs. Patients received 50 units botulinum toxin type A (n=15) or placebo (n=15). Outcome measures were monthly frequency and duration of migraine attacks and the number of severe attacks. Botulinum toxin type A produced significantly greater reductions in the frequency of migraine attacks of any severity at Day 90 (-3.14 vs. -0.53; p<0.05) and in the frequency of severe migraine attacks at Days 60 (-1.4 vs. -0.54; p<0.05) and 90 (-1.8 vs. -0.20; p<0.02). One patient in the botulinum toxin type A group experienced mild, transient frontalis muscle weakness lasting approximately 30 days. Botulinum toxin type A injections were well tolerated and provided effective migraine prophylaxis in these patients.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barrientos, N., Chana, P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 4, 146–151 (2003). https://doi.org/10.1007/s10194-003-0049-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10194-003-0049-2